We recently published a list of 10 Best Australian Stocks to Buy According to Billionaires. In this article, we are going to ...

Regenerative medicine, a rapidly advancing field, can be generally defined as a therapeutic methodology for the repair, ...

Manufacturing: As a result of FDA approval of RYONCIL in December 2024, the US$23.0 million provision against the value of inventory manufactured and expensed in prior periods was reversed and is now ...

Mesoblast stock surged after FDA approval of Ryoncil for SR-aGVHD, but market size is limited with NPV of ~$1B vs $2.33B market cap. Ryoncil faces commercialization challenges: second-line therapy ...

Investors are piling into Mesoblast shares on Monday. But why? The post Up 810% in a year, the Mesoblast share price is ...

Here's why analysts at Bell Potter think that Mesoblast Ltd (ASX: MSB) shares could still be cheap despite rallying hard ...

Ryoncil ® was approved in December 2024 by the United States Food and Drug Administration (FDA) for steroid-refractory acute graft-versus-host disease (SR-aGvHD) in pediatric patients 2 months ...

The analyst noted that the price of Ryoncil (the mesenchymal stromal cell therapy approved by the FDA) is approximately $1.55 million per treatment, which is justifiable due to its significant ...

NEW YORK, March 06, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced its addition to the S&P ...

Q2 2025 Earnings Conference Call February 26, 2025 5:00 PM ETCompany ParticipantsSilviu Itescu - Chief Executive ...

FDA approved Ryoncil® as the first and only therapy for pediatric patients 2 months and older, including adolescents and teenagers, with steroid-refractory acute graft versus host disease (SR ...